ROARABLE
FREE $100K
Today Screener Big Ideas Track Record 💰 $100K Arena 🎲 Predictions 🏛️ Insiders 8 Analysts
Stock Ratings / Health Care / AZN / financials
NVS (67) MRK (80) ABT (77) NVO (58) ⌘ Pro Terminal →

AstraZeneca PLC (AZN) Revenue-to-Profit Sankey Flow & SEC XBRL Financials

$186.58 -0.04% NYSE • Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $186.21

AstraZeneca PLC (AZN) carries a Roarable Rating of C+ (Hold) with 67/100 RQD Confidence. The composite score sits in the neutral Hold band (59–69), meaning current holders don’t need to panic-sell while prospective buyers can wait for a move into the 70+ Buy zone.

ROARABLE C+ • HOLD / WATCH Cap $289.44B
📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚡ INSTANT AI QUANT PREVIEW • $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on AZN Below — or Connect Your Own ChatGPT / Claude
🤖 Mara Quenwick • AI Quant Lead (Click for Instant Brief) Is AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
▼

As of 2026-11-03, AstraZeneca PLC (NYSE: AZN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $186.58 (-0.04% 1D, market cap $289.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AZN ranks #99 in composite RQD confidence.

✓ Pre-computed one-to-many AI Quant brief
🤖 Ellis Vennor • AI Peer & Flow Quant (Click for Instant Brief) How does AZN compare to NVS and MRK in the Health Care sector?
▼

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C+ (67/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (67/100 RQD, P/E 32.8x, ROIC 9.9%, cap $306.81B) and MRK (Merck & Company Inc.) posts a B+ grade (80/100 RQD, P/E 19.8x, ROIC 20.7%, cap $368.89B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).

✓ Pre-computed one-to-many AI Quant brief
🤖 Gideon Ashmere • AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for AZN?
▼

For AstraZeneca PLC (AZN), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

✓ Pre-computed one-to-many AI Quant brief
🤖 AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists — not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
🛡️ Portfolio Crash X-Ray
EXT / AFTER-HRS: $186.21 (-0.20%)🧬 Cannibal Buyback (-1.24% YoY Shares)⚙️ Cash Engine: 12/20 (C-) • 15.8% FCF Margin
Verify 90D Bucket Audit →
📊 Historical Track Record: Scores of 67/100 (C+) historically posted market-perform odds over rolling 90-day windows (+1.6% avg 90D alpha vs SPY • 56.4% hit rate — wait for RQD ≥ 70 breakout).
Audit Bucket Track Record →
RQD QUANT TACHOMETERHOLD / WATCH • C+
025507510067
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw C · Rk B-
Cash (12)Whales (15)SEC (16)Macro (12)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE+4.1% Base Target
$229 Bull$194 Base$151 Bear
📬 FREE AZN RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for AZN)Realized 20D OHLCV Swing Band: ±4.9%
Deterministic 5-Pillar Attribution (67/100 Composite)
🔍 WHY AZN SCORES 67/100 (C+) — TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
▲ #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (24% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) • Piotroski F-Score 8/9

▲ #2 Bullish Driver: Whale & Options Positioning+15/20 pts (22% of score)

20D Institutional Volume Accumulation (±4.9% realized swing band)

▼ #1 Drag / Risk Factor: Insider Conviction & Share Dilution12/20 pts (-8 pt drag)

Cannibal Buyback (-1.24% YoY Shares) & executive Form 4 sales trim 8 pts from alignment

📈 PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 → Q2 → Q3 → Current
Q1 (-3Q)
59
Grade C$162.03+4% Next Q
Q2 (-2Q)
62
Grade C+$168.45+0.6% Next Q
Q3 (-1Q)
64
Grade C+$169.51+10.1% Next Q
Current
67
Grade C+$186.58+1.6% Hist 90D α
Trajectory: C (59) → C+ (67)Full Audit →
⚔️ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)GIDEON ASHMERE // FORENSIC SHORT & KILL-SWITCH DOSSIER

⚔️ Adversarial Opposing Case: Why the AZN Bull Thesis Could Fail

Gideon Ashmere Forensic Desk →

Even with a 67/100 (C+) score, AZN faces multiple-compression risk if 32.8x trailing P/E re-rate toward historical sector medians or if hyperscaler/enterprise customer concentration slows in upcoming 10-Q filings.

⚠️ Forensic Kill-Switch #1

Broader market pullbacks can still drag down strong stocks in the short run.

⚠️ Forensic Kill-Switch #2

Dilution & Margin Drag: Cannibal Buyback (-1.24% YoY Shares) — any gross margin slip below 49.5% triggers an automatic RQD downgrade.

⚠️ Forensic Kill-Switch #3

Technical & Forensic Kill-Switch: A daily close below the 50D SMA ($165.14) or 200D SMA ($180.05) invalidates the momentum regime and cuts Target Base ($194.14) toward Bear Floor ($151.43).

🎲 LIVE PREDICTION MARKET ODDS TIED TO $AZN• $2.4M Crowd Pool • Kalshi / Polymarket Composite
Contract: “AZN Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 67%NO 33%Trade / Inspect Odds →
VISUAL REVENUE-TO-PROFIT SANKEY WATERFALL • Trailing 12 Months

How AZN Turns Every Dollar of Sales Into Real Bottom-Line Profit

Free Cash Flow:$6.40B (15.8% FCF Margin)
Revenue$40.52BGross Profit $21.07B (52%)Cost of Sales $19.45BOp Profit $5.63B (13.9%)OpEx (R&D/SG&A) $15.44BNet Profit$4.42B (10.9%)Tax/Other $1.22B
ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring AZN)

  • ✓Walkthrough of AZN's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • ✓3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • ✓Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) →$100K Arena
AZN // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +1.70%⚡ TESTING RESISTANCE
2026-11-03O $174.4H $186.7L $174.4C $186.6VOL 5.47M
RES: $189.0SUP: $154.2SMA50: $165.1SMA200: $180.1
$199.4$187.0$174.5$162.0$149.5RES $189.0SUP $154.2$186.62026-05-042026-06-182026-08-052026-09-212026-11-03
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

AZN Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 AZN Butterfly Map → + Track AZN →
Share Count & Dilution Monitor

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle
25.3%/yr Implied 5Y Growth

vs. +22.0% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger

No active Ellis Vennor swing setup published on AZN today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for AZN. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for AZN today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (AZN)

Health Care Rank #99 of 1015 ⚔️ NVS vs AZN Full Matrix →

1. Head-to-Head Health Care Peer Comparison (AZN vs. NVS, MRK, ABT, NVO)

Industry: Biotechnology: Pharmaceutical Preparations (489 Tracked Issuers)

Across 1015 tracked Health Care securities in the Roarable RQD universe, AstraZeneca PLC (AZN) ranks #99 by composite RQD confidence (67/100, grade C+) and #8 by equity capitalization ($289.44B). Within this direct 5-issuer industry benchmark cohort, MRK leads on earnings valuation at 19.8x trailing P/E, while MRK leads on capital efficiency and profitability with 20.7% ROIC and 74.8% gross margin. MRK currently holds the highest overall quantitative score in the immediate peer group at 80/100 (B+) compared with AZN at 67/100 (C+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
AZN ACTIVE
AstraZeneca PLC
C+ 67/100 32.8x — 9.9% -0.04% $289.44B Benchmark Subject
NVS
Novartis AG
C+ 67/100 32.8x — 9.9% +0.45% $306.81B /nvs-vs-azn →
MRK
Merck & Company Inc.
B+ 80/100 19.8x 74.8% 20.7% -0.78% $368.89B /mrk-vs-azn →
ABT
Abbott Laboratories
B+ 77/100 27.7x 56.4% 11.9% +3.73% $183.77B /abt-vs-azn →
NVO
Novo Nordisk A/S
D+ 58/100 32.8x — 9.9% +1.13% $177.12B /nvo-vs-azn →

2. AZN Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

AstraZeneca PLC (AZN) operates in Biotechnology: Pharmaceutical Preparations (Health Care) with an equity capitalization of $289.44B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of —, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. AZN Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is AZN stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-03, AstraZeneca PLC (NYSE: AZN) is rated C+ (Hold / HOLD) by Roarable's 5-pillar RQD engine with a composite confidence score of 67/100 at a spot price of $186.58 (-0.04% 1D, market cap $289.44B). Pillar breakdown: Fundamental Cash Engine 12/20, Institutional 13F & Options Flow 15/20, SEC Balance-Sheet Forensics 16/20, FRED Macro Regime Fit 12/20, and Executive Insider Alignment 12/20. Across 1015 tracked Health Care issuers, AZN ranks #99 in composite RQD confidence.

How does AZN compare to NVS and MRK in the Health Care sector?

Within the Health Care sector (Biotechnology: Pharmaceutical Preparations), AZN carries a Roarable C+ (67/100 RQD), trailing P/E of 32.8x, gross margin of —, and ROIC of 9.9%. By comparison, NVS (Novartis AG) holds a C+ grade (67/100 RQD, P/E 32.8x, ROIC 9.9%, cap $306.81B) and MRK (Merck & Company Inc.) posts a B+ grade (80/100 RQD, P/E 19.8x, ROIC 20.7%, cap $368.89B). Among the 5-stock peer group, MRK leads on earnings multiple (19.8x) while MRK leads on capital efficiency (20.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for AZN?

For AstraZeneca PLC (AZN), key quantitative strengths include Big institutional funds and options desks are actively positioning on the bullish side and Clean SEC annual filing review with no major hidden accounting time-bombs., while primary risk factors center on Broader market pullbacks can still drag down strong stocks in the short run and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is AZN trading relative to its 50-day, 200-day, and 52-week technical levels?

AZN last traded at $186.58 (-0.04% on volume of 2,699,448 shares), positioning the stock +12.98% above its 50-day simple moving average ($165.14) and +3.63% above its 200-day simple moving average ($180.05). Across its 52-week range of $153.41 to $212.71, AZN sits at the 55.9% percentile with a 14-day RSI of 66.3 (BULLISH MOMENTUM) and an implied next-earnings move of ±4.9% ($177.44 to $195.72).

Direct Sub-Reports: AZN RQD Cockpit AZN 12M Forecast AZN Earnings & Move AZN Dividends & DRIP AZN Insiders & 13F AZN Whale Options AZN Profit Sankey AZN News & Why
ROARABLE RATING BRIEF • RQD 67/100 (C+) ✓ SEC XBRL & RQD VERIFIED

AZN — AstraZeneca PLC: What the Facts Mean to a Prospective Investor

Methodology: RQD v6.2 Deterministic 5-Pillar & SEC XBRL Audit
Updated: 2026-11-03

1. Roarable Rating Brief: What This Means to a Prospective Investor

AstraZeneca PLC (AZN) earns a live Roarable RQD composite score of 67/100, corresponding to a C+ letter grade (Roarable Hold) at a spot price of $186.58 (-0.04% 1D, market capitalization $289.44B).

  • Fundamental Cash Engine (12/20): Anchored by return on invested capital (ROIC) of 9.9%, gross margin of —, operating margin of 13.9%, and free cash flow yield of 2.21%.
  • Whale 13F & Options Flow (15/20) + Insider Conviction (12/20): Tracks institutional 13F accumulation, CBOE options call/put positioning, and SEC Form 4 / Congressional PTR filings.
  • Macro Regime Fit (12/20) + Forensic Balance Sheet (16/20): Incorporates a 0.91x equity beta, Altman Z-Score of 3.74, Piotroski F-Score of 8/9, and Debt/Equity of 0.39x.

2. Business Model, Unit Margins & SEC Financial Trajectory

AstraZeneca PLC is a NYSE-listed issuer in the Health Care sector, within the Biotechnology: Pharmaceutical Preparations industry. Per the market data, operating margin is 13.9% and net margin is 10.9%. — for product lines, customer segments, or specific revenue-generation mechanics.

3. Institutional Bull vs. Bear Thesis & Valuation Tradeoff

  • 🐂 Primary Bull Case (C+ • RQD 67/100): Big institutional funds and options desks are actively positioning on the bullish side. Clean SEC annual filing review with no major hidden accounting time-bombs. With Fundamental Cash Engine at 12/20 and Institutional Whale Flow at 15/20, sustained execution supports upside toward the upper end of the $153.41 – $212.71 52-week range.
  • 🐻 Primary Bear Case & Valuation Risk: Broader market pullbacks can still drag down strong stocks in the short run. Investors must weigh 32.8x trailing P/E and 21.0x EV/EBITDA against 13.9% operating margins and a 0.91x macro beta.

4. 2nd-Order Butterfly Ripples & Key Questions to Watch

Upstream and downstream dependencies, sector correlations, and second-order bottlenecks are — The only relevant ripple evident in the news wire is the Ionis-partnered heart-drug trial miss referenced in the Stocktwits item, which investors may wish to track for pipeline read-through.

  • Key Question #1: Can AZN sustain or expand its 13.9% operating margin and 9.9% ROIC against Biotechnology: Pharmaceutical Preparations peers over the next 4 quarters?
  • Key Question #2: Will free cash flow conversion (2.21% FCF yield) strengthen balance-sheet liquidity (Altman Z-Score 3.74) toward the $212.71 52-week high?
  • Key Question #3: How sensitive is AZN's 27.6x forward P/E multiple to Health Care capital spending cycles and macro interest-rate shifts (Beta 0.91x)?

AZN Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for AstraZeneca PLC (AZN) • Click "Debate This Headline" to argue it in the Roar Pit below

💬 Jump to AZN Debate Forum (3) ↓
🔥 THE ROAR PIT • LIVE COMMUNITY DEBATE 3 Active Posts & Replies

AZN Bull vs. Bear Conversation Board — What's Your Call at $186.58?

🐂 67% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON AZN 🐻 33% BEARISH CONVICTION
1. Pick Your Side on AZN:
💡 Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
AL AlphaFlow_Cap RQD DEBATE OPENER • Verified $100K Arena Trader 🐂 BULLISH 🎯 Target: $218.38 (+17.0%)
📌 Pinned Debate

Forensic balance sheet scores 16/20 with Altman Z 3.74 and Piotroski F 8/9, and the CEO's pipeline commentary coincided with a stock ra

The street is overcomplicating AstraZeneca PLC (AZN). Forensic balance sheet scores 16/20 with Altman Z 3.74 and Piotroski F 8/9, and the CEO's pipeline commentary coincided with a stock rally.. With an RQD score of 67/100 (C+) and Forensic Balance Sheet at 16/20, any positive earnings surprise or guidance raise forces underweight funds to chase above $201.58.

ArenaChamp_24 🐂 BULL

@AlphaFlow_Cap Agree on the RQD 67/100 quality, though with 0.91 beta I'm scaling in with half-size at $186.65 and keeping dry powder in case we test $173.58.

SH ShortSeller_Dan RQD DEBATE OPENER • Forensic Short Bias 🐻 BEARISH 🎯 Target: $156.79 (-16.0%)
Spot @ $186.65

Trailing P/E of 32.8 against a 2.21% FCF yield and a 9/20 macro-regime-fit score leave limited valuation cushion.

I respect the product at AstraZeneca PLC, but the stock at $186.65 is a different story. Trailing P/E of 32.8 against a 2.21% FCF yield and a 9/20 macro-regime-fit score leave limited valuation cushion.. FCF yield is 2.21% and RQD sits at 67/100 (C+) — why pay up here when you can wait for next quarter's numbers?

LIVE TAPE SPY $752.10 -1.80% QQQ $681.09 -3.60% DIA $519.34 -1.08% IWM $279.14 -1.68% NVDA $202.06 -1.26% AAPL $338.32 -1.83% MSFT $507.12 -2.83% TSLA $403.82 +1.00% PLTR $178.34 -3.13% SOFI $16.60 -0.95% IBIT $43.35 -5.42% GLD $361.65 -3.59%